Skip to main content
Sign In

Daniel Chan, PhD

Professor, Division of Medical Oncology

 Dan Chan Photo

Education: PhD

University of Hawaii at Manoa, Honolulu, HI 
MSc 1974, PhD 1979


Dr. Chan joined the faculty of the Division of Medical Oncology in 1988 as an instructor. Before coming to University of Colorado Denver, Dr. Chan trained at the Cancer Research Center of Hawaii as a Junior Researcher and as an Assistant Research Professor after obtaining his PhD at the University of Hawaii at Manoa. He also trained as a postdoctoral fellow at the Center of Nuclear Studies in Grenoble, France. 

Dr. Chan’s research focus is in Lung Cancer. He has contributed richly in the field of Lung Cancer Research. Some of his accomplishments include registering over 8 patents with several pending and being awarded the 2006 School of Medicine Ph.D. Research and Teaching Award.

(selected from 95 peer-reviewed publications)
Witta, Samir, Helfrich B, Hirsch FR, Coldren C, Hedman K, Chan Z. Chan DC, Ravdel L,
Baron A, Franklin W, Drabkin HA, Minna JD, Gemmill RM, Bunn PA Jr: Restoring
E-cadherin expression increases sensitivity to EGFR inhibitors in lung cancer cell lines.
Cancer Research 66(2) 944-950, 2006.

Moody TW, Nakagawa T, Kang Y, Jakowlew S, Chan DC and Jensen RT: Bombesin/Gastrin
releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to
reduce lung cancer proliferation. J Mol Neurosci 28(3): 231-238, 2006.

Helfrich B, Raben D, Varella-Garcia, Gustafson D, Chan DC, Coldren C, Baron a, Zeng C, 
Franklin W, Hirsch F, Gazdar A, Minna J and Bunn PA Jr: Antitumor activity of the EGFR
tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in NSCLC cell lines and xenografts
correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clinical
Cancer Research 12(23): 7117-7125, 2006.

NIH-NCI “SPORE for Lung Cancers”.

NIH-NCI “SPORE for Lung Cancers, Alterations of E-Cadherin and SEMA3F in Lung Cancer”.

Eli-Lilly Pharmaceuticals,“In vitro and in vivo evaluation of 7 novel agents from Lilly for the
treatment of lung cancers.”

NIH-NCI “NQO1 inhibitors and pancreatic cancer therapy”

NIH-NCI STTR Phase 1 “Plasmin-activated prodrug therapy for pancreatic cancer”.

Biogen-Idec, “In vitro and in vivo efficacy of anti-IGF-1R antibodies in lung cancers.”

Eli Lilly Pharmaceuticals, Combined therapy with pemetrexed, carboplatin and CXCR4
antagonists in lung cancers.

PubMed Articles


University of Colorado Denver

© The Regents of the University of Colorado, a body corporate. All rights reserved.

All trademarks are registered property of the University. Used by permission only.